Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 15/20 | 0.36 |
| ▸ | CASP6 | P55212 | 15/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 15/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499200 | 0.83 | MEN1 (0.36) | PTGER4TSHRMEN1KMT2A | |
| SCHEMBL7200874 | 0.80 | CASP3 (0.40) | CASP3CASP6CASP8 | |
| SCHEMBL7200864 | 0.79 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL7207096 | 0.75 | CASP3 (0.53) | CASP3CASP6CASP8 | |
| SCHEMBL7619903 | 0.74 | KDM4E (0.39) | PTGER4TSHR | |
| SCHEMBL5668081 | 0.73 | KDM4E (0.36) | PTGER4TSHRKMT2A | |
| SCHEMBL5669685 | 0.73 | KDM4E (0.39) | PTGER4TSHR | |
| SCHEMBL8496435 | 0.73 | CASP1 (0.36) | PTGER4TSHRMEN1KMT2A | |
| SCHEMBL6740038 | 0.73 | KDM4E (0.38) | CASP3CASP6CASP8PTGER4TSHR | |
| SCHEMBL27564717 | 0.73 | CNR1 (0.38) | PTGER4TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6489353-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISORDERS | IDUN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP6 37/4885CASP8 60/4885 |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP6 37/4885CASP8 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.